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In situ analysis of biomarkers is highly desirable in
molecular pathology because it allows the examina-
tion of biomarker status within the histopathological
context of clinical specimens. Immunohistochemis-
try and DNA in situ hybridization (ISH) are widely
used in clinical settings to assess protein and DNA
biomarkers, respectively, but clinical use of in situ
RNA analysis is rare. This disparity is especially nota-
ble when considering the abundance of RNA biomark-
ers discovered through whole-genome expression
profiling. This is largely due to the high degree of
technical complexity and insufficient sensitivity and
specificity of current RNA ISH techniques. Here, we
describe RNAscope, a novel RNA ISH technology with
a unique probe design strategy that allows simultaneous
signal amplification and background suppression to
achieve single-molecule visualization while preserving
tissue morphology. RNAscope is compatible with rou-
tine formalin-fixed, paraffin-embedded tissue speci-
mens and can use either conventional chromogenic
dyes for bright-field microscopy or fluorescent dyes for
multiplex analysis. Unlike grind-and-bind RNA analysis
methods such as real-time RT-PCR, RNAscope brings the
benefits of in situ analysis to RNA biomarkers and may
enable rapid development of RNA ISH-based molecular
diagnostic assays. (J Mol Diagn 2012, 14:22–29; DOI:
10.1016/j.jmoldx.2011.08.002)
Biomarkers based on DNA, RNA, and proteins are in-
creasingly used for cancer diagnosis, prognosis, and
therapy guidance, heralding the era of personalized
medicine.1 RNA biomarkers or gene expression signa-
22tures have emerged as a major class of cancer biomark-
ers, thanks to widespread use of genome-wide gene
expression profiling technologies.2,3 To implement these
genomic signatures in clinical diagnostic assays, the cur-
rent platform of choice is real-time RT-PCR, which is
considered the gold standard in gene expression analy-
sis.4 However, this grind-and-bind approach has a seri-
ous drawback: the process of RNA extraction destroys
the tissue context of gene expression measurements,
making it impossible to map the observed signals to
individual cells. Furthermore, these assays are prone to
interference from unintended cell types (eg, noncancer
cells) and from unwanted tissue elements (eg, fibrosis
and necrosis). Microdissection techniques can alleviate
this problem to some extent,5,6 but they are too cumber-
some and laborious to be useful on a routine basis. By
contrast, DNA in situ hybridization (ISH)7 and protein im-
munohistochemistry (IHC)8 are routinely used in clinical
laboratories for DNA and protein biomarker analysis, al-
lowing the integration of molecular information with histo-
pathology for optimal clinical interpretation. To date, use
of RNA ISH in clinical diagnostics has been limited to
highly expressed genes such as Epstein-Barr virus
(EBV)-derived transcripts EBER1/2 in EBV-related dis-
eases.9,10 Conventional non-radioisotopic RNA in situ hy-
bridization (ISH) techniques lack the sensitivity and spec-
ificity required to measure many low-abundance RNA
biomarkers reliably.11
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method. Single-molecule visualization in individual cells
is achieved through use of a novel probe design strategy
and a hybridization-based signal amplification system to
simultaneously amplify signals and suppress back-
ground. Many of the steps in RNAscope are similar to
those in IHC. The RNAscope approach can be used with
archival formalin-fixed, paraffin-embedded (FFPE) tissue
samples on glass slides, and the stained slides can be
visualized under either a standard bright-field micro-
scope (with chromogenic labels) or an epifluorescent
microscope (with fluorescent labels). The RNAscope ap-
proach allows multiplex detection for up to four target
genes (limited by the number of spectrally discernible
fluorescent dyes). The ability to analyze gene expres-
sion in situ in routine clinical specimen types, as well as
high sensitivity and specificity, make RNAscope a
promising platform for translating many RNA biomark-
ers into clinical use.
Materials and Methods
Cell Culture
SK-BR-3 breast adenocarcinoma cells (ATCC, Manas-
sas, VA) were cultured in McCoy’s medium. HuH-7 hep-
atocellular carcinoma cells (JCRB-Japanese Collection
of Research Bioresources, Shinjuku, Japan) with or with-
out hepatitis C virus (HCV) infection were cultured in
modified Eagle’s medium. MCF7 breast adenocarcinoma
cells, SiHa cervical squamous cell carcinoma cells, HeLa
cervical adenocarcinoma cells, and MS751 cervical epi-
dermoid carcinoma cells (all from ATCC) were cultured in
Dulbecco’s modified Eagle’s medium at 37°C in 5% CO2.
MDA-MB-468 breast adenocarcinoma cells (ATCC) were
cultured in L-15 (Leibovitz) medium in a CO2-free incu-
bator at 37°C. All media were supplemented with 10%
fetal bovine serum (Gibco; Invitrogen, Carlsbad, CA).
Tissue Specimens
Deidentified archival FFPE tumor tissues were purchased
from Analytical Biological Services (Wilmington, DE). Tis-
sue quality was assessed by performing RNAscope anal-
ysis for mRNA of the housekeeping gene ubiquitin C
(UBC).
RNAscope Design Strategy
We sought to improve the signal-to-noise ratio of RNA ISH
by amplifying target-specific signals but not background
noise from nonspecific hybridization. We used a novel
target probe design strategy (a double-Z design) (Figure 1).
A series of target probes are designed to hybridize to the
target RNA molecule. Each target probe contains an 18-
to 25-base region complementary to the target RNA, a
spacer sequence, and a 14-base tail sequence (concep-
tualized as Z). A pair of target probes (double Z), each
possessing a different type of tail sequence, hybridize
contiguously to a target region (50 bases). The two tailsequences together form a 28-base hybridization site for
the preamplifier, which contains 20 binding sites for the
amplifier, which, in turn, contains 20 binding sites for the
label probe. Typically, a 1-kb region on the RNAmolecule
is targeted by 20 probe pairs; thus, sequential hybridiza-
tions with the preamplifier, amplifier, and label probe can
theoretically yield up to 8000 labels for each target RNA
molecule.
This hybridization-mediated signal amplification scheme
is similar to the branched DNA (bDNA) method de-
scribed previously,12 but the double-Z probe design
strategy should ensure superior background control
because it is highly unlikely that a nonspecific hybrid-
ization event will juxtapose a pair of target probes
along an off-target mRNA molecule to form the 28-base
hybridization site for the preamplifier, and also be-
cause a single 14-base tail sequence will not bind the
preamplifier with sufficient strength to result in suc-
cessful signal amplification.
The label probe can be either fluorescently labeled for
direct visualization under an epifluorescent microscope
or conjugated to an alkaline phosphatase or horseradish
peroxidase (HRP) molecule for chromogenic reactions
[Fast Red with alkaline phosphatase and 3,3=-diamino-
benzidine (DAB) with HRP]. The alkaline phosphatase or
HRP-labeled probes have an added advantage, in that
chromogen-stained slides can be viewed under a stan-
dard bright-field microscope similar to IHC procedures,
making RNAscope assay results easier to read and ar-
chive in a clinical setting.
Multiple RNA species can be measured simultane-
ously in two ways: the target probes for different genes
can have the same tail sequence recognized by the
same signal amplification system, generating a pooled
signal; alternatively, multiple signal amplification systems
with different label probes can be used to detect each
RNA species, allowing for multiplex detection of multiple
target RNAs.
Custom software was written to automatically select tar-
get probe sequences with compatible melting temperature
(Tm) and minimal cross-hybridization to off-target se-
quences.13 We determined that three probe pairs could
generate readily visible signals with HRP/DAB detection
Figure 1. Schematic of the RNAscope assay procedure. In step 1, cells or
tissues are fixed and permeabilized to allow for target probe access. In step
2, target RNA-specific oligonucleotide probes (Z) are hybridized in pairs (ZZ)
to multiple RNA targets. In step 3, multiple signal amplification molecules are
hybridized, each recognizing a specific target probe, and each unique label
probe is conjugated to a different fluorophore or enzyme. In step 4, signals
are detected using an epifluorescent microscope (for fluorescent label) or
standard bright-field microscope (for enzyme label).(see Supplemental Figure S1 at http://jmd.amjpathol.org).
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robustness against potentially variable target accessibility
and partial RNA degradation.
RNAscope Assay Procedure for RNA Detection
The target genes and probed regions are listed in Sup-
plemental Table S1 (available at http://jmd.amjpathol.
org). Sequences of target probes, preamplifier, amplifier,
and label probe are proprietary (Advanced Cell Diagnos-
tics, Hayward, CA). For fluorescent detection, the label
probe was conjugated to Alexa Fluor 488, 546, 647, or
750 (Molecular Probes; Invitrogen, Eugene, OR). For
chromogenic detection using DAB, label probe was con-
jugated to HRP.
For cell lines, cells were placed on slides and fixed in
4% formaldehyde for 60 minutes, followed by protease
digestion (2.5 g/mL) at 23°C to 25°C. The cells were
then incubated in order at 40°C with the following solu-
tions: target probes in hybridization buffer A [6 SSC (1
SSC is 0.15 mol/L NaCl, 0.015 mol/L Na-citrate), 25%
formamide, 0.2% lithium dodecyl sulfate, blocking re-
agents] for 3 hours; preamplifier (2 nmol/L) in hybridiza-
tion buffer B (20% formamide, 5 SSC, 0.3% lithium
dodecyl sulfate, 10% dextran sulfate, blocking reagents)
for 30 minutes; amplifier (2 nmol/L) in hybridization buffer
B at 40°C for 15 minutes; and label probe (2 nmol/L) in
hybridization buffer C (5 SSC, 0.3% lithium dodecyl
sulfate, blocking reagents) for 15 minutes. After each
hybridization step, slides were washed with wash buffer
(0.1 SSC, 0.03% lithium dodecyl sulfate) three times at
room temperature. For multiplex detection, equimolar
amounts of target probes, preamplifier, amplifier, and
label probe of each amplification system were used.
Chromogenic detection was performed using DAB fol-
lowed by counterstaining with hematoxylin (American
MasterTech Scientific, Lodi, CA).
For FFPE tissues, tissue sections in 5-m thickness
were deparaffinized in xylene, followed by dehydration in
an ethanol series. Tissue sections were then incubated in
citrate buffer (10 nmol/L, pH 6) maintained at a boiling
temperature (100°C to 103°C) using a hot plate for 15
minutes, rinsed in deionized water, and immediately
treated with10 g/mL protease (Sigma-Aldrich, St. Louis,
MO) at 40°C for 30 minutes in a HybEZ hybridization oven
(Advanced Cell Diagnostics, Hayward, CA). Hybridiza-
tion with target probes, preamplifier, amplifier, and label
probe and chromogenic detection were as described
above for cultured cells. A wide range of assay condi-
tions were explored to optimize for FFPE samples pre-
pared and fixed according to American Society of Clini-
cal Oncology/College of American Pathologists (ASCO/
CAP) guidelines14 (10% neutral buffered formalin for 6 to
72 hours at room temperature), including pretreatment
conditions such as citrate buffer temperature, pH, incu-
bation time, and protease concentrations.
Assays using archival FFPE specimens were typically
performed in parallel with positive and negative controls,
to ensure interpretable results. The endogenous house-
keeping gene UBC was used as positive control to as-
sess both tissue RNA integrity and assay procedure.Positive staining with signals easily visible under a 10
objective lens was considered to be adequate. The bac-
terial gene dapB was used as negative control to assess
background signals; completely negative staining was
routinely achieved using our standard protocol.
Conventional RNA ISH
A commercially available RISH kit (Biocare Medical, Con-
cord, CA) was used to detect immunoglobulin  chain
mRNA in human tonsil tissue according to the manufac-
turer’s protocol, in parallel with the RNAscope assay. No
negative control was provided in the kit.
Estimation of Copy Number
RNAscope for DNA ISH
Trypsinized cells were treated in a hypotonic solution
(0.075 mol/L KCl), washed, fixed in Carnoy’s fixative (3:1
methanol/acetic acid), and air-dried on slides. The cells
were then treated with RNase (Roche Diagnostics, Indi-
anapolis, IN), followed by 0.005% pepsin (Sigma-Aldrich)
treatment for 10 minutes at 37°C. DNA was denatured in
denaturing solution (75% formamide, 2 SSC) for 5 min-
utes at 75°C and then was subjected to probe hybridiza-
tion according to the RNAscope procedure described
above.
QuantiGene 2.0
HeLa cells were cultured in triplicate: one culture was
trypsinized, to get a cell count; another was lysed for
QuantiGene 2.0 (Panomics; Affymetrix, Fremont, CA)
analysis according to the manufacturer’s protocol; the
third was used for RNAscope analysis. The number of
HER2 mRNA transcripts in the cell lysate was determined
by using a standard curve constructed from known
amounts of in vitro transcribed RNA. The per-cell copy
number was determined by dividing the number of mRNA
molecules in the lysate by the number of cells used in the
assay. Confidence limits were estimated by linear regres-
sion based on triplicate measurements.
RNAscope
The number of HER2 mRNA transcripts determined by
RNAscope was based on the fluorescent spot count of
100 randomly selected cells in microscopic images.
The per-cell copy number was determined by dividing
the total spot count by the number of cells counted.
Microscopic Imaging
Images were acquired using an Olympus IX71 fluores-
cent microscope (Olympus, Tokyo, Japan) and a PXL37
CCD camera (Photometrics, Tucson, AZ). For multiplex
RNAscope staining and for studies with FFPE tissue
specimens, images were acquired using a Zeiss Ax-
ioplan M1 microscope (Carl Zeiss MicroImaging, Göttin-
gen, Germany) and a CRi Nuance multispectral imaging
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lapping signals from different fluorophores were sepa-
rated by comparing composite signals against a refer-
ence spectral library generated with single-color stained
samples.
Results
Validation of RNAscope Design Strategy
We hypothesized that selective amplification of target-
specific signals without amplifying background signal
should substantially improve signal-to-noise ratio,
thereby also improving both sensitivity and specificity in
RNA ISH. To achieve this goal, we developed a probe
design concept much akin to fluorescence resonance
energy transfer (FRET), in which two independent probes
(double Z probes) have to hybridize to the target se-
quence in tandem in order for signal amplification to
occur (Figure 1; see also under Materials and Methods).
Because it is highly unlikely that two independent probes
will hybridize to a nonspecific target right next to each
other, this design concept should in theory ensure selec-
tive amplification of target-specific signals.
To validate this probe design strategy, we first deter-
mined whether the paired target probes are necessary to
generate signals. The set of target probe pairs for 18S
ribosomal RNA was split into two groups, one consisting
of only the probes with the left tail and the other consist-
ing of only the probes with the right tail (Figure 2A). The
two groups of probes were hybridized either alone or in
combination with HeLa cells. A ubiquitous fluorescent
staining was observed when both groups were used
together, but no fluorescent signal was detected when
either group was used alone. The lack of visible signals
(indistinguishable from the control with no target
probe) from either half of the target probe pairs was
remarkable, considering the high levels of 18S rRNA
target molecules in the cells. This result confirmed that
the individual 14-base tails were not sufficient for bind-
ing to the signal amplification system under the assay
conditions.
To demonstrate assay specificity, a probe set targeting
HCV RNA was used to detect a viral transcript in HuH-7
cells stably infected with HCV. Positive punctate staining
was detected in HCV-infected cells, but not in uninfected
control cells (Figure 2B). To further determine the level of
specificity achievable, we stained several cell lines con-
taining different human papillomavirus (HPV) genotypes
with as much as 85% overall sequence identity.15 Each
target probe set gave positive staining only in the cell line
known to harbor the corresponding HPV genotype (see
Supplemental Figure S2 at http://jmd.amjpathol.org).
Multiplex Detection of mRNAs in Cell Lines
RNAscope, a probe hybridization-based assay, could
have better multiplexing capability than an antibody-
based IHC assay because the assay condition is univer-
sal to all RNA transcripts (which are located within the
cytoplasm) and because cross-hybridization betweenFigure 2. Validation of RNAscope. A: HeLa cells were hybridized with
either the full set of probes to 18S rRNA, the left half of the set, or the right
half of the set (as shown in the schematic along the top). A no-probe
control was performed in parallel as an indicator of background staining.
Cells were counterstained with DAPI (blue), which masks nucleolar 18S
RNA. Scale bar  10 m. B: HCV-uninfected (left) or HCV-infected
(right) HuH-7 cells were hybridized with probe sets to HCV mRNA
(green). Cells were costained with 18S rRNA target probes (red) as an
internal control for assay success. Nuclei were counterstained with DAPI
(blue). Original magnification, 40. C: HeLa cells were hybridized with
probes to -actin, RPLP0 (60S acidic ribosomal protein P0), PPIB (pepti-
dylprolyl isomerase B), and HPRT-1 (hypoxanthine phosphoribosyltrans-
ferase 1) in multiplex fluorescence format. Nuclei were counterstained
with DAPI. Original magnification, 40.
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algorithm. To demonstrate the ability of RNAscope to
detect multiple transcripts simultaneously, probe sets for
the housekeeping genes HPRT1, PPIB, RPLP0, and
ACTB (-actin) were labeled with fluorescent dyes of
different colors and hybridized to HeLa cells (Figure 2C).
All four genes showed distinct expression patterns con-
sistent with their known low, medium, and high expres-
sion levels. To determine whether multiplex analysis gave
quantitative results similar to those of single-gene analy-
sis, we detected mRNAs of HPRT1 and POLR2A in SK-
BR-3 cells either singly or in a duplex format. The dot
counts for each gene were similar for both single and
duplex hybridization (see Supplemental Table S2 at
http://jmd.amjpathol.org).
Single RNA Molecule Detection in Cell Lines
The punctate staining pattern seen for HCV, HPRT1,
PPIB, POLR2A, and RPLP0 raised the possibility that
each fluorescent dot in the RNAscope assay represents a
single mRNA transcript. We used two different methods
to test this. First, we used the same target probes to
detect human epidermal growth factor receptor 2 (HER2)
mRNA and genomic DNA in HeLa and SK-BR-3 cells
under identical target probe hybridization and signal am-
plification conditions. For genomic DNA, two fluorescent
dots were detected in HeLa cells, whereas many more
dots were seen in SK-BR-3 cells, consistent with the
diploid and amplified HER2 gene status in HeLa and
SK-BR-3 cells, respectively (Figure 3A). These results
demonstrate that the RNAscope assay is capable of sin-
gle-molecule nucleic acid detection. The same probe set
detected HER2 mRNA transcripts in HeLa and SK-BR-3
cells with dot numbers consistent with their gene ampli-
fication status (see Supplemental Figure S3A at http://
jmd.amjpathol.org). We then compared the signal intensi-
ties of HER2 mRNA dots with those of HER2 genomic
DNA dots. If the RNA staining represented more than one
mRNA transcript, then the signal intensity of at least some
of the mRNA dots would be expected to be greater than
the genomic DNA dots. However, no mRNA signal had a
fluorescent intensity greater than the maximum intensity
observed for genomic DNA (see Supplemental Figure
S3B at http://jmd.amjpathol.org). In fact, the signal distri-
bution of the RNA dots was skewed toward the lower end,
possibly because of the more restricted probe accessi-
bility or spatial localization of RNA. In a second test, we
counted the number of HER2 mRNA dots in HeLa cells
and compared that with the number of mRNA tran-
scripts determined in cell lysates by QuantiGene 2.016
(Figure 3, B and C). The dot number per cell determined
by RNAscope (mean  95% confidence limit, 14.4 
0.75; Figure 3B) agreed well with the copy number per
cell determined by QuantiGene (mean  95% confi-
dence limit, 17.0  0.96; Figure 3C). Taken together,
these results are consistent with each RNA dot deriving
from a single mRNA molecule.In Situ Detection of mRNA in FFPE Tissues
Because FFPE tissue is the most widely used clinical
sample type in cancer diagnosis, we adapted the
RNAscope assay for use on FFPE tissue and determined
its general applicability for staining various tissue types.
A probe set targeting the housekeeping gene UBC was
hybridized to archival breast, lung, and prostate FFPE
tissues, using standard tissue pretreatment in boiling ci-
Figure 3. Single RNA molecule detection. A: HER2 genomic DNA in HeLa
and SK-BR-3 cells was detected using the RNAscope probes and signal
amplification system. Nuclei were costained for IL-8 for diploid genome
Original magnification,40. B:HER2 mRNA detection in HeLa cells using the
same probes and signal amplification system. A probe set to 18S rRNA was
used as internal control for RNA detection. HER2 mRNA dots were counted;
mean dots per cell (95% confidence limit) are indicated. Nuclei were
counterstained with DAPI (blue). Original magnification, 40. C: HER2
mRNA copies per cell in HeLa cells determined by QuantiGene 2.0 (QG2)
using a standard curve from in vitro transcribed RNA. Mean copies per cell
(95% confidence limit) are indicated (green dot), as calculated from trip-
licate measurements using linear regression.trate buffer and protease digestion. Using HRP-conju-
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detected in all three tissue types, but no signal was
present when the negative control dapB probes were
used (Figure 4A).
To demonstrate the detection sensitivity of RNAscope
in FFPE tissue, we hybridized probe sets for two low-
expressing housekeeping genes, POLR2A and HPRT1, to
breast tumor tissues. Positive signals were observed for
both genes as discrete fluorescent dots (Figure 4B),
which are almost identical to those seen in cell lines,
suggesting the possibility of single-molecule detection.
We next compared RNAscope with a commercial non-
radioisotopic RNA ISH kit (RISH, Biocare, CA), used ac-
cording to the manufacturer’s protocol, for detecting im-
munoglobulin  chain expression in B lymphocytes in
human FFPE tonsil tissue. Plasma cells in the germinal
center express high levels of  light chain, whereas B
cells in the mantle zone express much lower levels of 
light chain, levels that cannot be reliably detected by
conventional non-radioisotopic ISH methods.17,18 In-
deed, both RNAscope and RISH detected strong staining
in plasma cells, although RNAscope staining was more
intense. Importantly, whereas RNAscope demonstrated
clear punctate staining in B cells in the mantle zone, RISH
generated only a faint diffuse pattern in these cells (Fig-
ure 5), a pattern that can be difficult to distinguish from
background.18
Multiplex Detection of mRNAs in FFPE Tissues
To demonstrate the multiplex ability of RNAscope in FFPE
tissues, we analyzed the expression of urokinase-type
plasminogen activator (uPA) and its inhibitor PAI-1 in
FFPE breast cancer tissues, together with cytokeratin
markers (pooled probes for CK-8, CK-18, and CK-19),
Figure 4. RNAscope detection of RNA in FFPE tumor tissues. A: Chromo-
genic staining (DAB) of primary tumor tissues (breast, lung, and prostate)
hybridized with either probes to ubiquitin C (UBC) or probes against the
bacterial gene dapB as negative control. Nuclei were counterstained with
hematoxylin. Original magnification, 40. B: Fluorescent detection of low-
copy transcripts in FFPE samples. Breast tumor tissue section was hybridized
with either no probes or with Alexa Fluor 488-labeled probe sets (green) to
HPRT1 or POLR2A. Nuclei were counterstained with DAPI (blue). Scale
bar  10 m.using a triplex fluorescence assay (Figure 6). uPA and
PAI-1 are among the most established prognostic mark-
ers in breast cancer.19,20 Consistent with previous stud-
ies,21,22 strong uPA and PAI-1 mRNA staining was seen
in tumor-associated stromal cells, but not in the tumor
epithelium. Furthermore, our results indicate that uPA and
PAI-1 mRNAs are rarely coexpressed in the same cell,
suggesting that these two proteins may be produced by
different stromal cell types.22
Discussion
Here, we have described the development and validation
of RNAscope, a novel non-radioisotopic RNA ISH tech-
nology that has the potential to be applied to routine
clinical samples for biomarker analysis. ISH, which has a
history of more than 40 years, has been continuously
improved over time.7,23–25 Nonetheless, limitations in
sensitivity and specificity and the time-consuming, com-
plex procedures involved have impeded its adoption in
clinical research and diagnostics.
Figure 5. Detection of Ig  chain expression in B lymphocytes in FFPE
human tonsil tissue.  light chain mRNA transcripts were stained using
RNAscope or a commercial non-radioisotopic RNA ISH kit. For RNAscope, a
negative control (bacterial gene dapB) was also included. The dotted line
outlines the mantle zone. Original magnification, 40.
Figure 6. Multiplex fluorescence detection of uPA and PAI mRNAs in breast
cancer. Merged pseudo-colored image of a metastatic breast cancer tissue
section stained with probes specific to cytokeratins [PanCK (CK-8, CK-18,
and CK-19), labeled with Alexa Fluor 647], uPA (labeled with Alexa Fluor
546), and PAI-1 (labeled with Alexa Fluor 488). Both uPA expression (ar-
rowhead and right inset) and coexpression with PAI-1 (arrow and left
inset) were detected. Nuclei were counterstained with DAPI (blue). Original
magnification, 40.
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have focused largely on improving sensitivity,7,23 either
by amplifying the mRNA targets before hybridization
(eg, in situ PCR26) or amplifying the signals after target
hybridization (eg, bDNA12 or tyramide signal amplifi-
cation27). Target amplification before hybridization
makes quantification problematic, because of amplifi-
cation bias, and signal amplification can also amplify
noise, limiting the achievable improvement in signal-
to-noise ratio. In contrast, RNAscope was designed to
amplify target-specific signals without also amplifying
the background, resulting in marked improvement in
signal-to-noise ratio. To date, we have developed RNA-
scope assays for more than 100 genes with varying
expression levels (unpublished data).
In analyzing biomarkers in FFPE tissues, preanalyti-
cal variables such as time from tissue acquisition to
fixation, fixatives used, and fixation time can negatively
affect the resulting biomarker measurements.14 We
found that reliable results could be obtained if tissues
were prepared and fixed according to ASCO/CAP
guidelines.14 The use of up to 20 target probe pairs,
each spanning 40 to 50 nucleotides along the target
RNA molecule, should provide additional robustness
against the partial RNA degradation characteristic of
FFPE samples.
Secreted proteins such as growth factors, cytokines,
and extracellular matrix proteins are increasingly being
used as therapeutic targets and diagnostic biomarkers.
In cases in which detecting these proteins by IHC may
lack sensitivity or cellular resolution (see, for example,
Beck et al18), detecting their mRNAs by RNAscope may
be an effective alternative, because mRNAs are localized
intracellularly.
In summary, RNAscope represents a significant im-
provement in RNA ISH methodology and is compatible
with clinical sample types and laboratory workflows.
Our research group has begun to test this assay in
routine clinical samples from clinical laboratories.28
Because the target probes are unmodified short oligo-
nucleotides and can be uniformly designed and man-
ufactured, RNAscope assays should be scalable to
whole transcriptomes with universal reagents and assay
conditions. Like other in situ methods, such as DNA ISH
and protein IHC, RNAscope holds significant promise as
a new platform for developing and implementing RNA-
based molecular diagnostics.
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